文献速递鼻科咽喉与嗓音

阿司匹林脱敏治疗阿司匹林加重性呼吸系统疾病的获益与危害:系统评价与Meta分析

Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-09-13

该系统评价与Meta分析纳入5项随机对照试验共233例阿司匹林加重性呼吸系统疾病(AERD)患者,比较阿司匹林脱敏(平均日剂量800 mg)与安慰剂的疗效与安全性。结果显示脱敏治疗可改善生活质量与呼吸道症状,但显著增加导致停药的不良事件及胃炎风险。

要点

  • 阿司匹林脱敏可改善AERD患者生活质量(RR 2.00)和呼吸道症状(RR 2.20)。
  • 脱敏治疗增加导致停药的不良事件风险(RR 4.39)和胃炎风险(RR 3.84)。
  • 证据质量:症状改善为高至中等确定性,不良事件为中等至低确定性。

核心结论

  • 在AERD患者中,中等至高等确定性证据表明阿司匹林脱敏可显著减轻鼻窦炎症状并改善生活质量,但显著增加不良事件。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE、Cochrane Central Register of Controlled Trials及WHO International Clinical Trials Registry Platform至2019年1月5日,纳入随机对照试验和比较性观察研究,共5项RCT纳入233例AERD患者。

主要发现

  • 与安慰剂相比,阿司匹林脱敏(平均日剂量800 mg)改善生活质量(RR 2.00;95%CI 1.31至3.06;I²=0%;RD +24%;SNOT-22评分MD -10.27;95%CI -6.39至-14.15;中等确定性)。
  • 阿司匹林脱敏改善呼吸道症状(RR 2.20;95%CI 1.55至2.73;I²=34%;RD +36%;AAO评分MD -2.56;95%CI -1.12至-3.92;高确定性)。
  • 阿司匹林脱敏增加导致治疗中断的严重不良事件(大出血、胃炎、哮喘急性发作或皮疹导致停药;RR 4.39;95%CI 1.43至13.50;I²=0%;RD +11%;中等确定性)。
  • 阿司匹林脱敏增加胃炎风险(RR 3.84;95%CI 1.12至13.19;I²=0%;RD +9%;低确定性)。
  • 两项观察性研究因缺乏混杂因素调整和/或同期对照而未提供有效信息。

关键数值与推荐

  • 生活质量改善:RR 2.00(95%CI 1.31至3.06),RD +24%,SNOT-22评分MD -10.27(95%CI -6.39至-14.15)。
  • 呼吸道症状改善:RR 2.20(95%CI 1.55至2.73),RD +36%,AAO评分MD -2.56(95%CI -1.12至-3.92)。
  • 导致停药的不良事件:RR 4.39(95%CI 1.43至13.50),RD +11%。
  • 胃炎风险:RR 3.84(95%CI 1.12至13.19),RD +9%。

临床怎么用

  • 对AERD患者,阿司匹林脱敏(平均日剂量800 mg)可考虑用于改善鼻窦炎症状和生活质量。
  • 治疗决策需权衡获益与不良事件风险,尤其是导致停药的不良事件和胃炎。

局限性

  • 纳入的RCT样本量较小(共233例患者)。
  • 两项观察性研究因缺乏混杂因素调整和/或同期对照而未提供有效信息。
  • 部分结局的证据确定性为中等或低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin desensitization is increasingly recommended for the treatment of aspirin-exacerbated respiratory disease (AERD). The objective of this study is to systematically review the efficacy and safety of aspirin desensitization in patients with AERD. METHODS: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) International Clinical Trials Registry Platform from inception to January 5, 2019. We included randomized trials and comparative observational studies in any language. Data extraction and risk of bias assessment were performed in duplicate independently. RESULTS: Five randomized controlled trials (RCTs) enrolled 233 patients with AERD. Compared to placebo, aspirin desensitization (mean daily dose 800 mg) improved quality of life (risk ratio [RR] 2.00; 95% confidence interval [CI], 1.31 to 3.06; heterogeneity measure [I2 ] = 0%; risk difference [RD] +24%; 22-item Sino-Nasal Outcome Test [SNOT-22] scale [0 to 110, higher worse]; mean difference [MD] -10.27 [95% CI, -6.39 to -14.15]; moderate-certainty); and respiratory symptoms (RR 2.20 [95% CI, 1.55 to 2.73], I2 = 34%, RD +36%; American Academy of Otolaryngology (AAO) scale [0 to 20, higher worse]; MD -2.56 [95% CI,-1.12 to -3.92]; high-certainty). Aspirin desensitization increased adverse events severe enough to cause treatment discontinuation (major bleeding, gastritis, asthma exacerbation, or rash causing drug discontinuation, RR 4.39 [95% CI, 1.43 to 13.50], I2 = 0%, RD +11%, moderate-certainty), and gastritis (RR 3.84 [95% CI, 1.12 to 13.19], I2 = 0%, RD +9%, low-certainty). Findings were robust to sensitivity analyses. Two available observational studies were not informative because they lacked adjustment for confounders and/or contemporaneous controls. CONCLUSION: In patients with AERD, moderate-certainty and high-certainty evidence shows that aspirin desensitization meaningfully reduces symptoms of rhinosinusitis and improves quality of life, but results in a significant increase in adverse events.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Chu DK, Lee DJ, Lee KM, et al. Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2019. PMID: 31518069. doi:10.1002/alr.22428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。